Back to today’s briefing

Story perspectives

FDA Approves First-Ever Treatment for IgG4-RD

4/7/2025

25 5

Summary

Story summary

The FDA has made a groundbreaking decision by approving Uplizna, the first-ever treatment for adults battling immunoglobulin G4-related disease (IgG4-RD). This innovative therapy, which targets CD19+ B cells, demonstrated an impressive 87% reduction in disease flares during clinical trials. Priced at $140,248.50 per dose, Uplizna also provides valuable patient support programs.

1 of 1

Story summary

The FDA has made a groundbreaking decision by approving Uplizna, the first-ever treatment for adults battling immunoglobulin G4-related disease (IgG4-RD). This innovative therapy, which targets CD19+ B cells, demonstrated an impressive 87% reduction in disease flares during clinical trials. Priced at $140,248.50 per dose, Uplizna also provides valuable patient support programs.